Why Recombinant DNA Construct Design Determines Protein and Antibody Expression Success

Recombinant DNA technology allows researchers to build expression constructs for antibodies, enzymes, cytokines and other proteins. But a construct that is correct on the DNA sequence level can still produce low yield, poor secretion, incomplete assembly or unstable protein.

The distinction between recombinant DNA and recombinant protein matters. The DNA is the biological instruction set for production. It contains information, such as promoter context, coding-sequence design, codon-usage, signal peptide, chain arrangement and vector compatibility which all influence the final protein yield. evitria helps teams optimize that through its recombinant antibody expression service and transient CHO expression of recombinant antibodies, turning a defined sequence into purified, analytically assessed material for downstream research.

Recombinant DNA, Recombinant Protein and GMO Are Not the Same

Recombinant DNA is an intentionally engineered DNA molecule usually by a cloning strategy. It may combine a promoter, secretion signal, coding sequence and termination elements in a plasmid, or place genetic parts in a new arrangement. A recombinant protein is the product expressed from that engineered template. A monoclonal antibody purified from cell-culture supernatant is therefore a recombinant protein, not recombinant DNA.

A genetically modified organism, or GMO, is a living organism whose genetic material has been altered. A plasmid in a tube and a purified protein are not organisms. A bacterial or mammalian cell carrying engineered DNA is genetically modified. Keeping these terms separate makes project goals clearer: construct design defines the DNA template, the host cell executes the production, and purification recovers the protein product.

The Cloning Strategy Must Fit the Construct

Modern cloning began with restriction enzymes and ligases. The construction of functional recombinant plasmids by Cohen and colleagues helped establish the field in the 1970s ¹. Today, researchers can choose among several assembly methods. No method is best for every project; the decision should reflect fragment number, throughput, junction requirements, sequence complexity and future reuse ²³.

The variety of cloning strategies mainly represent the way of how one or several DNA fragments (usually produced by chemical synthesis, cutting it from another source via restriction enzymes or copying from a template by PCR), encoding the gene of interest is pasted into an expression vector. But the main steps of cloning remain the same across the different methods:

Isolation and preparation of insert. Chemical synthesis, PCR or restriction digestion can be used to create the piece you want to copy

Preparation of vector. Most commonly a circular bacterial plasmid that is used for expressing the gene of interest. The vector is cut in one of the ways explained below.

Ligation or assembly. The prepared insert and vector are mixed together and annealed or assembled in any of the below ways.

Transformation. The new recombinant DNA is introduced into a host organism, usually E. Coli bacteria.

Selection and screening. The host cells are grown on selective medium, such as agar plate with antibiotics. Only the cells that took up the plasmid with the antibiotic resistance gene will survive.

Verification. Colony PCR, restriction digests, or DNA sequencing are used to verify the final product.

The different cloning strategies (representing the ways in which insert and vector are combined), include:

Restriction–ligation. A familiar and economical choice for simple constructs when suitable restriction sites are available. The DNA (vector and insert) is cut with specific restriction enzymes, creating overhangs. Ligase joins the compatible ends of insert and vector back together, creating a complete, circular plasmid. Internal sites and unwanted junction sequences can limit flexibility.

TA or TOPO cloning. A fast and simple method to directly insert PCR products into a plasmid vector. Taq Polymerase adds a single adenine to the 3’ end of the PCR products and the vectors are cut to have a complementary thymine overhang. Does not take into account directionality.

Gibson or isothermal assembly. Gibson Assembly is a seamless method used to join multiple DNA fragments in a single isothermal reaction without relying on specific restriction enzyme sites. 5’ exonuclease chews back the 5’ ends of the DNA fragment, creating overhangs that can anneal with the complementary part of the vector. DNA polymerase fills in the remaining gap and DNA Ligase seals the nicks in the backbone. Repeated sequences and poor overlap design can reduce success ⁴.

Golden Gate cloning. A fast method in one tube. It uses special type IIS enzymes that cut outside of their own recognition site. Because the cut site is separate, it can be freely chosen. Digestion and ligation happen at the same time in one tube. Internal recognition sites may need to be removed before assembly ⁵.

Recombination-based cloning. Efficient when the same insert must move through several destination vectors. A prominent example is the gateway cloning system from Thermo Fisher. IT relies on special recombination proteins, such as integrases and specific recognition sites in the donor vector, such as “attachment sites” (att). Recombination sequences, reagent cost and dependence on a defined system are practical constraints.

LIC or SLIC. Ligation-independent approaches create complementary overhangs for seamless cloning. The inherent 3’->5’ exonucleases activity of T4 DNA polymerase in the absence of nucleotides is used to create overhangs. They are economical and flexible but depend on careful primer and overhang design. After annealing the insert with the vector, transformation can take place and repair of remaining gaps as well as ligation happens directly inside the bacteria.

After the cloning step, full-sequence verification remains essential, especially for antibody panels in which a small frame, junction or chain-assignment error can invalidate an entire comparison. Long-read whole-plasmid sequencing is increasingly useful for detecting structural errors, rearrangements and repeat-region problems that may be missed by limited confirmation reads ⁶.

Expression Depends on the Complete Construct Architecture

The coding sequence is only one part of an expression cassette. Promoter and enhancer context influence transcription. The Kozak sequence and 5′ untranslated region affect translation initiation. Coding-sequence composition can influence messenger RNA stability, secondary structure, cryptic splicing and translation kinetics. Signal peptides control entry into the secretory pathway, while linkers, tags and cleavage sites can alter folding or processing.

Codon optimization can improve expression, but it does not guarantee higher yield. Changes in codon use may also change RNA structure or translation speed. In CHO cells, coding-sequence design and signal-peptide choice can materially affect antibody production ⁷⁸. Protein-specific signal peptides may outperform one universal leader, which supports testing a focused design panel instead of assuming one sequence will suit every molecule ⁹.

Antibodies add another variable because heavy and light chains must be expressed and assembled in a productive ratio. Separate vectors, dual cassettes and multicistronic designs handle this control differently. A small CHO expression pilot can show whether the proposed architecture and ratio supports secretion, intact assembly and usable product quality before a larger production campaign.

A Correct Sequence Can Still Fail During Expression

Sequence confirmation rules out cloning errors, but it does not prove that the protein will behave correctly. Low output may arise from weak transcription, unstable RNA, inefficient translation, intracellular retention, proteolysis, aggregation or host-cell stress. CHO expression reflects interacting genetic and cellular factors, so a design that works well for one protein may underperform for another ¹⁰.

The most useful approach is to connect construct verification with expression and QC. Concentration alone can hide poor assembly or aggregation. Titer analysis, electrophoretic profile, size-exclusion analysis and binding activity help distinguish a design problem from a culture or purification problem. evitria’s high-throughput antibody production service and CHO-based production workflow can provide this experimental bridge between an engineered sequence and assay-ready material.

CRISPR Edits the Host Genome Rather Than Simply Building a Plasmid

CRISPR is related to recombinant DNA technology, but it serves a different purpose. Cloning assembles an expression construct. CRISPR makes a targeted change in a chromosome directly in an organism.

It has multiple applications in medicine and gene therapy, correcting genetic mutations behind inherited disorders, agriculture, developing climate-resilient crops or in research, knocking out specific genes to study their effect.

Of course, human gene editing leads to an ethical and philosophical debate around how much we should be allowed to interfere and correct certain genetic traits and where is the line between necessary medical cure and artificial enhancement.

The process is derived from a natural immune defense system in bacteria and can be roughly divided into 3 main steps:

• Guide RNA (gRNA) is a synthetic RNA molecule designed to match a specific target sequence in the genome.
• Cas9 Enzyme is a protein that acts like molecular scissors to cut the DNA at the exact spot located by the guide RNA.
• Cellular Repair: The cell naturally repairs the cut using processes like
• non-homologous end joining: used for knocking out a gene as it is error-prone and adds deletions to the affected gene
• homology-directed repair (HDR): for knocking in a new gene, which is added via a donor DNA template alongside the CRISPR machinery. This will be used as template for HDR and the new gene inserted.

In CHO cell engineering, CRISPR can support targeted integration, gene knockout, pathway regulation and changes intended to improve productivity, glycosylation or host-cell protein profiles ¹¹¹².

Recent work has also moved beyond testing one edited clone at a time. Stable CHO knockout pools have been evaluated in multiplexed configurations targeting up to seven genes, illustrating how pooled CRISPR workflows can increase screening throughput while reducing the influence of clonal heterogeneity ¹³.

CRISPR still brings additional validation needs, including editing efficiency, off-target activity and genome stability. It does not replace construct design but is a step downstream when a host genome needs to be changed.

The Future Is Automated, Multiplexed and Data-Guided

DNA construction is moving from one-at-a-time cloning toward automated design–build–test–learn cycles. Automated high-throughput DNA synthesis and assembly can connect oligonucleotide production, robotic liquid handling and standardized build workflows at larger scale ¹⁴. Artificial intelligence can help flag problematic motifs, prioritize variants, choose the right codons and untranslated regions and plan assemblies.

Prediction is not proof. AI-generated designs still require physical assembly, full-sequence confirmation, expression testing and analytical assessment. The strongest systems will learn from reliable biological measurements rather than from sequence predictions alone.

How Better Construct Design Improves Expression Success

A stronger recombinant protein workflow starts with the intended molecule and final use in mind: Define the protein and host → design the complete expression cassette → choose the assembly method → verify the full construct → run a CHO expression pilot → assess yield, integrity and function → scale the validated design

This sequence prevents teams from treating cloning, expression and QC as unrelated tasks. It also provides a clear point for iteration: if the construct is correct but secretion or assembly remains poor, the next design can target the signal peptide, untranslated region, chain arrangement or other evidence-supported variables.

Key Takeaway

Recombinant DNA construction succeeds only when the engineered sequence produces the intended protein in a useful form. The cloning method should match the available fragments, while the complete vector should match the molecule and host. evitria supports this construct-to-protein transition through transient CHO production of recombinant antibodies and other secreted proteins, with purification and analytical assessment options for downstream research.

Planning an antibody or other secreted-protein expression project? Contact evitria to discuss how a defined sequence can be converted into research-ready material.

1. Cohen, S. N., Chang, A. C. Y., Boyer, H. W., & Helling, R. B. (1973). Construction of biologically functional bacterial plasmids in vitro. Proceedings of the National Academy of Sciences, 70(11), 3240–3244. https://doi.org/10.1073/pnas.70.11.3240 ↩︎
2. Casini, A., Storch, M., Baldwin, G. S., & Ellis, T. (2015). Bricks and blueprints: Methods and standards for DNA assembly. Nature Reviews Molecular Cell Biology, 16(9), 568–576. https://doi.org/10.1038/nrm4014 ↩︎
3. Chao, R., Yuan, Y., & Zhao, H. (2015). Recent advances in DNA assembly technologies. FEMS Yeast Research, 15(1), 1–9. https://doi.org/10.1111/1567-1364.12171 ↩︎
4. Gibson, D. G., Young, L., Chuang, R.-Y., Venter, J. C., Hutchison, C. A., III, & Smith, H. O. (2009). Enzymatic assembly of DNA molecules up to several hundred kilobases. Nature Methods, 6(5), 343–345. https://doi.org/10.1038/nmeth.1318 ↩︎
5. Bird, J. E., Marles-Wright, J., & Giachino, A. (2022). A user’s guide to Golden Gate cloning methods and standards. ACS Synthetic Biology, 11(11), 3551–3563. https://doi.org/10.1021/acssynbio.2c00355 ↩︎
6. Hernandez, S. I., Berezin, C.-T., Miller, K. M., & Peccoud, J. (2024). Sequencing strategy to ensure accurate plasmid assembly. ACS Synthetic Biology, 13(12), 4099–4109. https://doi.org/10.1021/acssynbio.4c00539 ↩︎
7. Haryadi, R., Ho, S., Kok, Y. J., et al. (2015). Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells. PLOS ONE, 10(2), e0116878. https://doi.org/10.1371/journal.pone.0116878 ↩︎
8. Srila, W., Baumann, M., Borth, N., & Yamabhai, M. (2022). Codon and signal peptide optimization for therapeutic antibody production from Chinese hamster ovary (CHO) cell. Biochemical and Biophysical Research Communications, 622, 157–162. https://doi.org/10.1016/j.bbrc.2022.06.072 ↩︎
9. O’Neill, P., Mistry, R. K., Brown, A. J., & James, D. C. (2023). Protein-specific signal peptides for mammalian vector engineering. ACS Synthetic Biology, 12(8), 2339–2352. https://doi.org/10.1021/acssynbio.3c00157 ↩︎
10. Li, Z.-M., Fan, Z.-L., Wang, X.-Y., & Wang, T.-Y. (2022). Factors affecting the expression of recombinant protein and improvement strategies in Chinese hamster ovary cells. Frontiers in Bioengineering and Biotechnology, 10, 880155. https://doi.org/10.3389/fbioe.2022.880155 ↩︎
11. Glinšek, K., Bozovičar, K., & Bratkovič, T. (2023). CRISPR technologies in Chinese hamster ovary cell line engineering. International Journal of Molecular Sciences, 24(9), 8144. https://doi.org/10.3390/ijms24098144 ↩︎
12. Kalkan, A. K., Palaz, F., Sofija, S., et al. (2023). Improving recombinant protein production in CHO cells using the CRISPR-Cas system. Biotechnology Advances, 64, 108115. https://doi.org/10.1016/j.biotechadv.2023.108115 ↩︎
13. Marzluf, J. P., Kirchmeier, D., Klein, J., et al. (2025). Utilizing stable gene-edited knockout pools for genetic screening and engineering in Chinese hamster ovary cells. Biotechnology Journal, 20(5), e70033. https://doi.org/10.1002/biot.70033 ↩︎
14. Ma, Y., Zhang, Z., Jia, B., & Yuan, Y. (2024). Automated high-throughput DNA synthesis and assembly. Heliyon, 10(6), e26967. https://doi.org/10.1016/j.heliyon.2024.e26967 ↩︎